Sun Pharmaceutical Industries Limited · NSE:SUNPHARMA
Sun Pharmaceutical Industries — Ranbaxy Laboratories — Q3 2013 Earnings Presentation
18 slides from Sun Pharmaceutical Industries's earnings presentation, Oct 29, 2013
Slide 1: Financial Results: July – September 2013 (Q3)
Ranbaxy Laboratories Limited FINANCIAL RESULTS: July – September 2013 (Q3) YTD September 30, 2013 (YTD Sep) ARUN SAWHNEY CEO & MD Dept. 29 Oct Name 2013 Post Results Conference Call Privileged and Confidential
Slide 2: Safe Harbor
Safe Harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “p
Slide 3: Key Achievements for Quarter 3, 2013
1/2 Key Achievements for Quarter 3, 2013 Financial Base business sales continued to grow over the corresponding quarter as continued focus on branded business 26,685 27,502 16% Percent Rs. Mn 7% Q3 2012 Q3 2013 Q3 2012 Q3 2013 Sales EBITDA/ Sales % Growth calculated on Constant Forex Privileged an
Slide 4: Highlights: Quarter 3, 2013
2/2 Highlights: Quarter 3, 2013 Received approval to market Synriam™ Business (Plasmodium Vivax) from CDSCO Branded category sales Rs.14,678 Mn 53% of sales for the Quarter Generic including API sales Rs.12,824 Mn India: USA: Pricing policy and trade related Strong prescription growth
Slide 5: Functional Performance
Functional Performance Manufacturing and Regulatory Mohali SEZ unit received an import alert and was subsequently included under certain provisions of the Consent Decree by the US FDA Made further improvements since the last inspection Stringent steps taken to ensure compliance Ohm plant rec
Slide 6: Other Areas
Other Areas Research & Development Regulatory Filings and approvals DF filings: 43; DF approvals: 40 3 ANDA filed in USA; YTD Sep 2013: 7 ANDA filings Derivatives Position Exposure down to ~$763 Mn as on 30 Sep 2013 from ~860 Mn in Q2 2013. Maturity: ~$33 Mn/month Debt Debt $922 Mn; Cash &
Slide 7: Other Areas
Other Areas Annual Guidance: 2013 Rs.130 Bn- Rs.135 Bn sales for the 15 month period ended 31 Mar 2014 Sales contribution from exclusivities will be accounted for as they materialize Change in Accounting Year Adopted the Financial Year i.e. April to March for the closing of its accounts This
Slide 8: Financial Performance
Ranbaxy Laboratories Limited Financial Performance FINANCIAL RESULTS: July – September 2013 (Q3) YTD September 30, 2013 (YTD Sep) Dept. Name Privileged and Confidential
Slide 9: Sales Performance
Sales Performance Rs. Mn Consolidated Sales Consolidated Sales Q3 2013 YTD Sep 2013 95,821 77,452 27,502 26,685 (6%) (23%) Q3 2012 Q3 2013 YTD Sep 12 YTD Sep 13 Sales growth seems lower due to pricing policy, trade concerns in India and absence of large post exclusivity sales of Atorvastatin Growt
Slide 10: North America
North America Rs. Mn 44,826 Major markets -USA -Canada 23,382 9,181 8,754 (15%) (52%) Q3 2012 Q3 2013 YTD Sep 12 YTD Sep 13 Strong prescription growth in Absorica™ continued Corresponding period sales higher aided by continued contribution from exclusivities Growth calculated on Constant Forex P
Slide 11: India
India Rs. Mn 16,600 16,004 5,729 5,748 - 4% Q3 2012 Q3 2013 YTD Sep 12 YTD Sep 13 Sales for the quarter impacted by pricing policy and trade related supply disruptions: Post the implementation of the new DPCO, trade bodies have demanded for higher margins as per the old structure Trade bodies
Slide 12: East Europe & CIS
East Europe & CIS Rs. Mn Major markets -Romania -Russia 11,636 -Ukraine 9,374 4,771 3,342 24% 13% Q3 2012 Q3 2013 YTD Sep 12 YTD Sep 13 Improvement in East Europe aided by New product launches and volume growth of existing portfolio Overall growth in CIS including strong OTC performance Growth c
Slide 13: West Europe
West Europe Rs. Mn Major markets -France 7,471 -Germany -UK 5,998 2,480 2,023 (31%) (27%) Q3 2012 Q3 2013 YTD Sep 12 YTD Sep 13 Regional focus on profitability Growth calculated on Constant Forex Privileged and Confidential 13
Slide 14: Asia Pacific & Latin America
Asia Pacific & Latin America Rs. Mn Major markets 6,016 -ANZ 5,631 -Malaysia -Brazil 2,275 1,880 14% 2% Q3 2012 Q3 2013 YTD Sep 12 YTD Sep 13 Strong performance across Australia, Brazil, Philippines and Myanmar Robust growth in Australia, the largest market in the APAC region (ex Japan) Growth c
Slide 15: Africa & Middle East
Africa & Middle East Rs. Mn 8,269 Major markets 7,351 -South Africa -Nigeria 2,458 2,252 4% 12% Q3 2012 Q3 2013 YTD Sep 12 YTD Sep 13 Sales impacted by reduced tender quantity Growth calculated on Constant Forex Privileged and Confidential 15
Slide 16: API & Others
API & Others Rs. Mn 5,551 5,163 1,821 1,474 (28%) 1% Q3 2012 Q3 2013 YTD Sep 12 YTD Sep 13 Impacted by change in regulations and lower demand Growth calculated on Constant Forex Privileged and Confidential 16
Slide 17: Financials Q3 2013: INR
Financials Q3 2013: INR Q3 '12 YTD Sep '12 Particulars Q3' 13 YTD Sep '13 5,881 16,532 -Within India 5,911 17,083 20,804 79,289 - Outside India 21,591 60,369 26,685 95,821 Sales 27,502 77,452 397 1,664 Other operating income 515 1,624 27,082 97,485 Total Operating Income 28,016 79,077 10,374 29,056
Slide 18: Questions & Answers
Questions & Answers Dept. Name Privileged and Confidential